270 related articles for article (PubMed ID: 22127346)
1. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Ushijima K; Kamura T; Tamura K; Kuzuya K; Sugiyama T; Noda K; Ochiai K
Int J Clin Oncol; 2013 Feb; 18(1):126-31. PubMed ID: 22127346
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
Polyzos A; Kosmas C; Toufexi H; Malamos N; Lagadas A; Kosmidis C; Ginopoulos P; Ziras N; Kandilis K; Georgoulias V
Anticancer Res; 2005; 25(5):3559-64. PubMed ID: 16101180
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
[TBL] [Abstract][Full Text] [Related]
5. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
Shoji T; Takatori E; Omi H; Kumagai S; Yoshizaki A; Yokoyama Y; Mizunuma H; Fujimoto T; Takano T; Yaegashi N; Tase T; Nakahara K; Kurachi H; Nishiyama H; Sugiyama T
Int J Gynecol Cancer; 2011 Jan; 21(1):44-50. PubMed ID: 21330830
[TBL] [Abstract][Full Text] [Related]
8. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
[TBL] [Abstract][Full Text] [Related]
9. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
Nishio S; Sugiyama T; Shouji T; Yoshizaki A; Kitagawa R; Ushijima K; Kamura T
Gynecol Oncol; 2007 Aug; 106(2):342-7. PubMed ID: 17499346
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
Matsumoto K; Katsumata N; Shibata T; Satoh T; Saitou M; Yunokawa M; Takano T; Nakamura K; Kamura T; Konishi I
Gynecol Oncol; 2015 Feb; 136(2):218-23. PubMed ID: 25449313
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
Shoji T; Takatori E; Omi H; Kagabu M; Honda T; Futagami M; Yokoyama Y; Kaiho M; Tokunaga H; Otsuki T; Takano T; Yaegashi N; Kojimahara T; Ohta T; Nagase S; Soeda S; Watanebe T; Nishiyama H; Sugiyama T
Cancer Chemother Pharmacol; 2017 Aug; 80(2):355-361. PubMed ID: 28656383
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
Matsumoto K; Katsumata N; Saito I; Shibata T; Konishi I; Fukuda H; Kamura T
Jpn J Clin Oncol; 2012 Mar; 42(3):222-5. PubMed ID: 22323553
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Aravantinos G; Bafaloukos D; Fountzilas G; Christodoulou C; Papadimitriou C; Pavlidis N; Kalofonos HP; Gogas H; Kosmidis P; Dimopoulos MA
Ann Oncol; 2003 Jul; 14(7):1094-9. PubMed ID: 12853352
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
[TBL] [Abstract][Full Text] [Related]
15. Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
Liu Y; Ren Z; Xu S; Bai H; Ma N; Wang F
Cancer Chemother Pharmacol; 2015 Mar; 75(3):645-51. PubMed ID: 25599660
[TBL] [Abstract][Full Text] [Related]
16. Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
Ota T; Takeshima N; Takizawa K
Eur J Gynaecol Oncol; 2011; 32(5):471-5. PubMed ID: 22053655
[TBL] [Abstract][Full Text] [Related]
17. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
20. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Song Z; Shao L; Lin B; Zhang Y
Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
